MY166821A - Anti-robo4-antibody - Google Patents

Anti-robo4-antibody

Info

Publication number
MY166821A
MY166821A MYPI2014703067A MYPI2014703067A MY166821A MY 166821 A MY166821 A MY 166821A MY PI2014703067 A MYPI2014703067 A MY PI2014703067A MY PI2014703067 A MYPI2014703067 A MY PI2014703067A MY 166821 A MY166821 A MY 166821A
Authority
MY
Malaysia
Prior art keywords
antibody
present
robo4
angiogenesis
pharmaceutical composition
Prior art date
Application number
MYPI2014703067A
Other languages
English (en)
Inventor
Yoshitaka Isumi
Toshiyuki Sato
Jun Hasegawa
Tatsuya Inoue
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2012103929A external-priority patent/JP2013230115A/ja
Priority claimed from JP2013011042A external-priority patent/JP2014141434A/ja
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MY166821A publication Critical patent/MY166821A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
MYPI2014703067A 2012-04-27 2013-04-26 Anti-robo4-antibody MY166821A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012103929A JP2013230115A (ja) 2012-04-27 2012-04-27 抗ｒｏｂｏ４抗体
JP2013011042A JP2014141434A (ja) 2013-01-24 2013-01-24 抗ｒｏｂｏ４抗体

Publications (1)

Publication Number Publication Date
MY166821A true MY166821A (en) 2018-07-23

Family

ID=48670623

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014703067A MY166821A (en) 2012-04-27 2013-04-26 Anti-robo4-antibody

Country Status (22)

Country Link
US (2) US9683040B2 (OSRAM)
EP (1) EP2841457B1 (OSRAM)
JP (2) JP5897205B2 (OSRAM)
KR (2) KR101950898B1 (OSRAM)
CN (1) CN104768973B (OSRAM)
AU (1) AU2013254313B2 (OSRAM)
BR (1) BR112014026649A2 (OSRAM)
CA (1) CA2868074A1 (OSRAM)
CO (1) CO7111295A2 (OSRAM)
DK (1) DK2841457T3 (OSRAM)
ES (1) ES2733434T3 (OSRAM)
IN (1) IN2014DN07799A (OSRAM)
MX (1) MX356749B (OSRAM)
MY (1) MY166821A (OSRAM)
NZ (1) NZ629291A (OSRAM)
PH (1) PH12014502382B1 (OSRAM)
PL (1) PL2841457T3 (OSRAM)
RU (1) RU2682451C2 (OSRAM)
SG (1) SG11201405718QA (OSRAM)
TW (1) TWI606065B (OSRAM)
WO (1) WO2013160879A1 (OSRAM)
ZA (1) ZA201406235B (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY166821A (en) * 2012-04-27 2018-07-23 Daiichi Sankyo Co Ltd Anti-robo4-antibody
SI3354729T1 (sl) 2015-09-24 2024-05-31 Daiichi Sankyo Company, Limited Protitelesa anti-garp
JPWO2018070390A1 (ja) * 2016-10-12 2019-08-22 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
KR20210070643A (ko) 2019-12-05 2021-06-15 김명배 자체 발전 웨어러블 다리
EP4479427A1 (en) 2022-02-16 2024-12-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-robo4 human monoclonal antibodies and uses thereof for the treatment of cancer
WO2025045139A1 (zh) * 2023-08-31 2025-03-06 舒泰神（北京）生物制药股份有限公司 特异性识别robo2的抗体及其应用
CN117384290B (zh) * 2023-12-11 2024-04-09 苏州因特药物研发有限公司 人源robo1结合分子及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
DK1024191T3 (da) 1991-12-02 2008-12-08 Medical Res Council Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
JPH09506508A (ja) 1993-12-03 1997-06-30 メディカル リサーチ カウンシル 組換え結合タンパク質およびペプチド
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
ES2296829T3 (es) * 2000-11-06 2008-05-01 Cancer Research Technology Limited Imaginologia, diagnostico y tratamiento de la enfermedad.
JP4583638B2 (ja) * 2001-03-15 2010-11-17 独立行政法人科学技術振興機構 アセチルリジン認識モノクローナル抗体及びその製造方法
WO2004003163A2 (en) 2002-06-27 2004-01-08 University Of Utah Research Foundation Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis
CA2506724C (en) * 2002-11-20 2013-03-12 Cancer Research Technology Limited Antibodies, polypeptides and uses thereof
DE602004002275T2 (de) 2003-01-07 2007-09-06 Symphogen A/S Verfahren zur herstellung rekombinanterpolyklonaler proteine
WO2008073441A2 (en) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
CA2676766A1 (en) * 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
TWI480050B (zh) * 2009-02-10 2015-04-11 Daiichi Sankyo Co Ltd 抗－ｍｓｔ１ｒ抗體及其用途
MY166821A (en) * 2012-04-27 2018-07-23 Daiichi Sankyo Co Ltd Anti-robo4-antibody

Also Published As

Publication number Publication date
WO2013160879A1 (en) 2013-10-31
JP6267733B2 (ja) 2018-01-24
KR20150008074A (ko) 2015-01-21
US9562096B2 (en) 2017-02-07
JP5897205B2 (ja) 2016-03-30
ZA201406235B (en) 2016-07-27
RU2014147616A (ru) 2016-06-20
NZ629291A (en) 2016-09-30
PH12014502382A1 (en) 2015-01-12
MX2014012351A (es) 2015-01-12
KR20190020838A (ko) 2019-03-04
CO7111295A2 (es) 2014-11-10
US20160108120A1 (en) 2016-04-21
AU2013254313B2 (en) 2017-03-30
AU2013254313A1 (en) 2014-09-18
CN104768973A (zh) 2015-07-08
JP2016175893A (ja) 2016-10-06
EP2841457A1 (en) 2015-03-04
PL2841457T3 (pl) 2019-09-30
US20150098945A1 (en) 2015-04-09
HK1207093A1 (en) 2016-01-22
EP2841457B1 (en) 2019-04-24
CA2868074A1 (en) 2013-10-31
MX356749B (es) 2018-06-12
TWI606065B (zh) 2017-11-21
TW201348257A (zh) 2013-12-01
DK2841457T3 (da) 2019-07-22
IN2014DN07799A (OSRAM) 2015-05-15
RU2682451C2 (ru) 2019-03-19
CN104768973B (zh) 2019-01-22
SG11201405718QA (en) 2014-10-30
BR112014026649A2 (pt) 2017-07-18
US9683040B2 (en) 2017-06-20
JP2015515490A (ja) 2015-05-28
PH12014502382B1 (en) 2015-01-12
KR101950898B1 (ko) 2019-02-22
ES2733434T3 (es) 2019-11-29

Similar Documents

Publication Publication Date Title
PH12014502382B1 (en) Anti-robo4-antibody
HUE049171T2 (hu) Rák diagnózisban felhasználható Claudin 18.2 elleni antitestek
GEP201606548B (en) Process for the preparation of treprostinil and derivatives thereof
HRP20190057T1 (hr) Konjugati kvetiapina s masnom kiselinom, postupak izrade i uporaba istih
ZA201600589B (en) Enabling payments to be processed by only one merchant
SI2855687T1 (sl) Mikroorganizmi in metode za proizvodnjo 4-hidroksibutirat, 1,4-butandiola in sorodne spojine
SG11201601363YA (en) Process for purifying an acid composition comprising 2-formyl-furan-5-carboxylic acid and 2,5-furandicarboxylic acid
CL2014003598A1 (es) Composición de lechada de cal de reactividad elevada que contiene particulas de cal apagada en suspension en fase acuosa y procedimiento de produccion de dicha lechada.
PT2888590T (pt) Anticorpos para olanzapina e utilização destes
WO2014209905A3 (en) Methods and compositions for detecting and diagnosing diseases and conditions
SG11201405270UA (en) Method for the production of polyols and uses thereof
EP3031914A4 (en) MODIFIED AMADORIASE AND METHOD FOR PRODUCING SAME, AGENT FOR IMPROVING SURFACTANT-RESISTANCE OF AMADORIASE AND COMPOSITION FOR MEASURING HbA1c USING SAME
SG11201601468UA (en) Catalyst for producing bio-based acrylic acid and its derivatives and the method for making thereof
EP2984935A4 (en) PROTEIN COMPOSITION AND METHOD FOR MANUFACTURING THE SAME
IN2014MN02114A (OSRAM)
PL3055679T3 (pl) Środek do wykrywania pęknięć, sposób jego wytwarzania i zastosowanie środka do wykrywania pęknięć
MX2015003034A (es) Jeringa que contiene una composicion, en particular farmaceutica, que comprende inmunoglobulinas, su metodo de fabricacion y uso.
EP3049142A4 (en) CATHETER ADDITIVE AND METHOD FOR THE PRODUCTION AND USE THEREOF
IN2014DN07407A (OSRAM)
SG11201406708XA (en) Itq-49 material, method for the production thereof and use of same
IN2014MN01871A (OSRAM)
EP2735547B8 (fr) Nouveau procédé de production d'eau allégée en calcaire et dispositif de mise en oeuvre
HK40107372A (en) Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
IN2013MU02428A (OSRAM)
EP2827773A4 (en) METHOD AND SYSTEM FOR THE AMPLIFICATION AND MEASUREMENT OF BREATH ANALYTICS